Adherence to oral amoxicillin dispersible tablets in children with community-acquired pneumonia enrolled in clinical trials in Malawi

Ginsburg, Amy Sarah; May, Susanne

doi:10.1186/s41479-021-00089-4

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following initial study drug administration, children were typically observed in-hospital for 2 days, discharged on day 3 if no treatment failure criteria (World Health Organization general danger sign (lethargy or unconsciousness, convulsions, vomiting everything, inability to drink or breastfeed), sign of severe respiratory distress (grunting, nasal flaring, head nodding, or chest indrawing), or hypoxemia) were present, and followed for 14 days to track clinical outcomes. At all scheduled (days 2, 4, 6, and 14), and unscheduled follow-up visits, children were assessed for treatment failure (primary endpoint, day 6 with a relative non-inferiority margin of 1.5 times the treatment failure rate in the 5-day amoxicillin group) or relapse, and study drug adherence 11 . All adverse events were assessed and managed per local standard clinical practice, documented, and followed and treated until resolution or stabilization.…”

Section: Methodsmentioning

confidence: 99%

Analysis of serious adverse events in a pediatric community-acquired pneumonia randomized clinical trial in Malawi

Ginsburg

May

2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Amoxicillin is recommended as first-line antibiotic treatment for community-acquired pneumonia, the leading infectious cause of mortality in children aged less than 5 years. We conducted a double-blind, randomized controlled non-inferiority trial comparing 3- to 5-day amoxicillin treatment for non-severe chest-indrawing pneumonia in HIV-negative children aged 2 to 59 months in Malawi. In a secondary analysis, we assessed the frequency of serious adverse events (SAEs) during the trial to evaluate the safety of treatment with amoxicillin. Enrolled children with non-severe chest-indrawing pneumonia were randomized to either 3- or 5-day amoxicillin and followed for 14 days to track clinical outcomes. In addition to evaluation for treatment failure (primary endpoint, day 6), relapse, and study drug adherence, children were assessed for adverse events, including SAEs, which were managed per local standard clinical practice until resolution or stabilization. Between March 2016 and April 2019, 3000 children were enrolled, with male and younger children (aged less than 24 months) demonstrating more SAEs (10.3% for males vs 8.1% for females, p = 0.04; 10.0% for 2–6 months, 10.8% for 7–11 months, 9.7% for 12–23 months and 5.6% for 24–59 months, p = 0.01). The most common SAEs were progression of or recurrent pneumonia (220 SAEs in 217 children), acute gastroenteritis (14 SAEs in 14 children), and fever (8 SAEs in 8 children); however, there were no significant or substantive differences in the percentage of children with pneumonia-related, acute gastroenteritis, or fever SAEs noted between the 3- versus 5-day amoxicillin treatment groups. In our pediatric community-acquired pneumonia trial evaluating amoxicillin treatment, there were relatively few SAEs overall and very few attributed to amoxicillin. Duration of amoxicillin treatment did not impact the frequency of SAEs. We found male and younger children appear to be more vulnerable to SAEs in our trial; however, our data support previous data demonstrating the safety of amoxicillin use in children with pneumonia.Clinical trial registration: ClinicalTrials.gov (NCT02678195).

show abstract

Section: Methodsmentioning

confidence: 99%